Data / Form D filings / LipimetiX Development, Inc.
LipimetiX Development, Inc.: Form D filing
LipimetiX Development, Inc., a pharmaceuticals company in Natick, ME, filed a Form D with the SEC in 2016. The latest, on September 8, 2016, reports $1 million sold of an offering with no set size to 12 investors.
Find out what LipimetiX Development, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 5 COMMONWEALTH ROAD, SUITE 2A, Natick, ME, 01760
- Phone
- (602) 286-5520
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2012
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1683387
The full lists. Form D filings in Maine: 101 rows, $5.05, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2016 | New notice | Indefinite | $1,011,606 | Indefinite | 12 | Aug 25, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| PHILLIP M FRIDEN, PH.D. | Executive Officer, Director | |
| ERIC M MORREL, PH.D. | Executive Officer, Director | |
| JOHN M HOLLIMAN, III | Executive Officer, Director | |
| DENNIS I GOLDBERG, PH.D. | Executive Officer, Director | |
| RANDOLPH C STEER, M.D., PH.D. | Executive Officer, Director |
Every Form D from the week of Sep 5, 2016 · All recent filings in Maine · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what LipimetiX Development, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.